X0206 3 2023-06-22 0 0001636282 Aeglea BioTherapeutics, Inc. AGLE 0001802528 Fairmount Funds Management LLC 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001686157 Fairmount Healthcare Fund L.P. 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001769651 Fairmount Healthcare Fund II L.P. 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001982220 Fairmount Healthcare Co-Invest L.P. 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001830177 Kiselak Tomas 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001663607 Harwin Peter Evan 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false Common Stock 276082 I By Fairmount Healthcare Fund LP( Common Stock 9184458 I By Fairmount Healthcare Fund II LP Stock Option (Right to Buy) 0.30 2033-06-22 Common Stock 1950000 I By Peter Harwin Stock Option (Right to Buy) 0.30 2033-06-22 Common Stock 1950000 I By Tomas Kiselak Series A Preferred Stock Common Stock 12675000 I By Fairmount Healthcare Fund LP Series A Preferred Stock Common Stock 424362000 I By Fairmount Healthcare Fund II LP Series A Preferred Stock Common Stock 85887000 I By Fairmount Healthcare Co-Invest LP Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest LP. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations. The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC. /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC 2023-06-30 /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund LP 2023-06-30 /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II LP 2023-06-30 /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Co-Invest LP 2023-06-30 /s/ Tomas Kiselak 2023-06-30 /s/ Peter Harwin 2023-06-30